188 related articles for article (PubMed ID: 25266309)
1. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.
Melenhorst JJ; Castillo P; Hanley PJ; Keller MD; Krance RA; Margolin J; Leen AM; Heslop HE; Barrett AJ; Rooney CM; Bollard CM
Mol Ther; 2015 Jan; 23(1):179-83. PubMed ID: 25266309
[TBL] [Abstract][Full Text] [Related]
2. Generation of alloreactive anti-leukemic cytotoxic T lymphocytes with attenuated GVHD properties from haploidentical parents in childhood acute lymphoblastic leukemia.
Jurickova I; Waller EK; Yeager AM; Boyer MW
Bone Marrow Transplant; 2002 Nov; 30(10):687-97. PubMed ID: 12420208
[TBL] [Abstract][Full Text] [Related]
3. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
[TBL] [Abstract][Full Text] [Related]
4. [Graft-versus-leukemia effect by lymphocytes from the first donor after second cord blood transplantation in a patient with T-lymphoblastic lymphoma].
Nagai K; Hashimoto H; Itoh K; Matsushita A; Shimoji S; Kimura T; Inoue D; Mori M; Nagai Y; Tabata S; Yanagida M; Takahashi T
Rinsho Ketsueki; 2010 Jun; 51(6):413-21. PubMed ID: 20622488
[TBL] [Abstract][Full Text] [Related]
5. Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1.
Kasai M; Akatsuka Y; Emi N; Taji H; Kohno A; Abe A; Tanimoto M; Kodera Y; Saito H
Int J Hematol; 1999 Feb; 69(2):112-8. PubMed ID: 10071461
[TBL] [Abstract][Full Text] [Related]
6. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction.
Montagna D; Daudt L; Locatelli F; Montini E; Turin I; Lisini D; Giorgiani G; Bernardo ME; Maccario R
Cancer Res; 2006 Jul; 66(14):7310-6. PubMed ID: 16849581
[TBL] [Abstract][Full Text] [Related]
7. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
Leen AM; Christin A; Myers GD; Liu H; Cruz CR; Hanley PJ; Kennedy-Nasser AA; Leung KS; Gee AP; Krance RA; Brenner MK; Heslop HE; Rooney CM; Bollard CM
Blood; 2009 Nov; 114(19):4283-92. PubMed ID: 19700662
[TBL] [Abstract][Full Text] [Related]
9. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
Rooney CM; Smith CA; Ng CY; Loftin S; Li C; Krance RA; Brenner MK; Heslop HE
Lancet; 1995 Jan; 345(8941):9-13. PubMed ID: 7799740
[TBL] [Abstract][Full Text] [Related]
10. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity.
Montagna D; Yvon E; Calcaterra V; Comoli P; Locatelli F; Maccario R; Fisher A; Cavazzana-Calvo M
Blood; 1999 May; 93(10):3550-7. PubMed ID: 10233908
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
Blair A; Goulden NJ; Libri NA; Oakhill A; Pamphilon DH
Blood Rev; 2005 Nov; 19(6):289-300. PubMed ID: 16275419
[TBL] [Abstract][Full Text] [Related]
12. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse.
Martelli MF; Di Ianni M; Ruggeri L; Falzetti F; Carotti A; Terenzi A; Pierini A; Massei MS; Amico L; Urbani E; Del Papa B; Zei T; Iacucci Ostini R; Cecchini D; Tognellini R; Reisner Y; Aversa F; Falini B; Velardi A
Blood; 2014 Jul; 124(4):638-44. PubMed ID: 24923299
[TBL] [Abstract][Full Text] [Related]
13. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.
Micklethwaite KP; Savoldo B; Hanley PJ; Leen AM; Demmler-Harrison GJ; Cooper LJ; Liu H; Gee AP; Shpall EJ; Rooney CM; Heslop HE; Brenner MK; Bollard CM; Dotti G
Blood; 2010 Apr; 115(13):2695-703. PubMed ID: 20110422
[TBL] [Abstract][Full Text] [Related]
14. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
[TBL] [Abstract][Full Text] [Related]
15. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.
Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH
Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118
[TBL] [Abstract][Full Text] [Related]
16. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
17. An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice.
Nijmeijer BA; Willemze R; Falkenburg JH
Blood; 2002 Jul; 100(2):654-60. PubMed ID: 12091361
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy following allogeneic bone marrow transplantation.
Dazzi F; Goldman JM
Annu Rev Med; 1998; 49():329-40. PubMed ID: 9509267
[TBL] [Abstract][Full Text] [Related]
19. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
[TBL] [Abstract][Full Text] [Related]
20. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q; Burton R; Reddy V; Lucas KG
Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
